Metamark Genetics, Inc., a leader in providing critical diagnostic and prognostic information to enable more informed treatment decisions for urological cancer, announced that effective May 25, 2016, the Company has signed an agreement with

Anthem Blue Cross Blue Shield of Georgia to provide its members with in-network access to Metamark's comprehensive suite of urology specialized diagnostic offerings.

"Metamark is making important strides in our mission to be the leading provider of essential, decision-making information to urologists and their patients throughout the complete prostate cancer care continuum," said Jerry Williamson, president and chief executive officer. "We're very pleased with our new agreement with Anthem BCBS of Georgia, which expands the availability of our innovative diagnostic and prognostic testing. There is a growing recognition among payers nationwide of the benefits from our distinctive approach to delivering critical information to enable more informed and personalized treatment decisions."

Metamark has previously announced in-network agreements with additional large BCBS plans, and also has agreements in place with the largest PPO networks in the country.